CoChat

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score

Open access
Zhu, Andrew X., Baron, Ari David, Malfertheiner, Peter, Kudo, Masatoshi, Kawazoe, Seiji, Pezet, Denis, Weissinger, Florian, Brandi, Giovanni, Barone, Carlo A., Okusaka, Takuji, Wada, Yoshiyuki, Park, Joon Oh, Ryoo, Baek-Yeol, Cho, Jae Yong, Chung, Hyun Cheol, Li, Chung-Pin, Yen, Chia-Jui, Lee, Kuan-Der, Chang, Shao-Chun, Yang, Ling, Abada, Paolo B., Chau, Ian · 2017 · JAMA Oncology
Cited by 88

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

IMPORTANCE: REACH is the first phase 3 trial to provide information on hepatocellular cancer (HCC) in the second-line (postsorafenib) setting categorized by Child-Pugh score, a scoring system used to measure the severity of chronic liver disease. This exploratory analysis demonstrates the relationship between a potential ramucirumab survival benefit, severity of liver disease, and baseline α-fetoprotein (αFP). OBJECTIVE: To assess treatment effects and tolerability of ramucirumab by Child-Pugh score in patients with HCC enrolled in the REACH trial. DESIGN, SETTINGS, AND PARTICIPANTS: Randomized, double-blind, phase 3 trial of ramucirumab and best supportive care vs placebo and best supportive care as second-line treatment in patients with HCC enrolled between November 4, 2010 and April 18, 2013, from 154 global sites. Overall, 643 patients were randomized and included in this analysis; 565 patients considered Child-Pugh class A (Child-Pugh scores 5 and 6) and 78 patients considered class B (Child-Pugh scores 7 and 8). INTERVENTIONS: Ramucirumab (8 mg/kg) or placebo intravenously plus best supportive care every 2 weeks. MAIN OUTCOMES AND MEASURES: Overall survival (OS), defined as time from randomization to death from any cause. RESULTS: In the randomized population of 643 patients (mean [SD] age, 62.8 [11.1] years) in this analysis, a potential ramucirumab OS benefit was observed for patients with a Child-Pugh score of 5 (hazard ratio [HR], 0.80; 95% CI, 0.63-1.02; P = .06) but no apparent benefit for patients with Child-Pugh scores of 6 or 7 and 8. In patients with baseline αFP levels of 400 ng/mL (to convert ng/mL to μg/L, multiply by 1.0) or more, a ramucirumab OS benefit was significant for a score of Child-Pugh 5 (HR, 0.61; 95% CI, 0.43-0.87; P = .01) and Child-Pugh 6 (HR, 0.64; 95% CI, 0.42-0.98; P = .04), but was not significant for Child-Pugh 7 and 8. The overall safety profile of ramucirumab, regardless of Child-Pugh score, was considered manageable. Regardless of treatment arm, patients with Child-Pugh scores of 7 and 8 experienced a higher incidence of grade 3 or higher treatment-emergent adverse events, including ascites and asthenia, and special-interest events, including liver injury and/or failure and bleeding, compared with patients with Child-Pugh scores of 5 or 6. CONCLUSIONS AND RELEVANCE: In unselected patients, a trend for ramucirumab survival benefit was observed only for patients with a Child-Pugh score of 5. In patients with baseline αFP levels of 400 ng/mL or more, a ramucirumab survival benefit was observed for Child-Pugh scores of 5 and 6. Ramucirumab had a manageable toxic effect profile. These results support the ongoing REACH-2 study of ramucirumab in patients with advanced HCC with underlying Child-Pugh A cirrhosis and baseline αFP levels of 400 ng/mL or more. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01140347.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2016.4115

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 88

Metadata

Authors
Zhu, A. X., Baron, A. D., Malfertheiner, P., Kudo, M., Kawazoe, S., Pezet, D., Weissinger, F., Brandi, G., Barone, C. A., Okusaka, T., Wada, Y., Park, J. O., Ryoo, B.-Y., Cho, J. Y., Chung, H. C., Li, C.-P., Yen, C.-J., Lee, K.-D., Chang, S.-C., Yang, L., Abada, P. B., & Chau, I.
Venue
JAMA Oncology
Published
2017-02-01
Volume
3
Issue
2
Pages
235
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2521441342
Cited by
88
References
2
FWCI
7.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. https://app.cochat.ai/papers/10.1001/jamaoncol.2016.4115
The paper
Zhu, A. X., Baron, A. D., Malfertheiner, P., Kudo, M., Kawazoe, S., Pezet, D., Weissinger, F., Brandi, G., Barone, C. A., Okusaka, T., Wada, Y., Park, J. O., Ryoo, B.-Y., Cho, J. Y., Chung, H. C., Li, C.-P., Yen, C.-J., Lee, K.-D., Chang, S.-C., . . . Chau, I. (2017). Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2016.4115

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.